Could We Soon Have a Specific Treatment for the Rare Disease IgA Nephritis?

It's Time to Remind About Travere Therapeutics
The time has come to remind that the U.S. FDA is reviewing Travere Therapeutics’ (TVTX) New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for IgA Nephritis (IgAN).

We remind that the FDA has assigned a Prescription Drug User Fee Act (

This content is for paid subscribers.
Please click here to subscribe or here to log in.